[{"id":"c7542cdd-da8d-4ac4-95c5-3669e4f55e19","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420779","created_at":"2022-06-15T15:55:33.113Z","updated_at":"2024-07-02T16:35:04.867Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations","source_id_and_acronym":"NCT05420779","lead_sponsor":"Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HR positive","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Halaven (eribulin mesylate) • TSL1502"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-08"}]